Mankind Pharma Q2 profit rises 38% to Rs 716 crore
Mankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337.9 crore compared to ₹3,697.2 crore in the same quarter last year. This growth is attributed to strong performance in both domestic and international markets. The recent acquisition of Armed Cell Therapeutics is expected to enhance R&D capabilities.
New Delhi: Mankind Pharma on Monday posted a 37.7% rise in profit to ₹716 crore in the September quarter, driven by strong business growth in domestic and international markets.Read more: Paytm Q2 Results: Profit rockets 976% YoY to Rs 226 crore, revenue jumps 28%The company had posted a profit after tax (PAT) of ₹520.2 crore in the year-ago period, according to a regulatory filing. Revenue from operations increased to ₹4,337.9 crore during the quarter under review as against ₹3,697.2 crore in the year-ago period, the company said in a regulatory filing.Read more: Tata Consumer Q2 Results: Net profit rises 16% YoY to Rs 470 crore, revenue up 14%"Our disciplined execution and strengthening business fundamentals resulted in strong performance.
